- Home
- CNTA vs WGS Comparison
CNTA vs WGS Comparison
Compare CNTA & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTA
- WGS
- Stock Information
- Founded
- CNTA 2020
- WGS 2017
- Country
- CNTA United Kingdom
- WGS United States
- Employees
- CNTA N/A
- WGS N/A
- Industry
- CNTA Biotechnology: Pharmaceutical Preparations
- WGS Retail: Computer Software & Peripheral Equipment
- Sector
- CNTA Health Care
- WGS Technology
- Exchange
- CNTA Nasdaq
- WGS Nasdaq
- Market Cap
- CNTA 2.3B
- WGS 2.0B
- IPO Year
- CNTA 2021
- WGS N/A
- Fundamental
- Price
- CNTA $17.16
- WGS $77.00
- Analyst Decision
- CNTA Strong Buy
- WGS Strong Buy
- Analyst Count
- CNTA 7
- WGS 5
- Target Price
- CNTA $23.71
- WGS $67.00
- AVG Volume (30 Days)
- CNTA 705.7K
- WGS 542.2K
- Earning Date
- CNTA 11-12-2024
- WGS 02-18-2025
- Dividend Yield
- CNTA N/A
- WGS N/A
- EPS Growth
- CNTA N/A
- WGS N/A
- EPS
- CNTA N/A
- WGS N/A
- Revenue
- CNTA $6,853,000.00
- WGS $267,228,000.00
- Revenue This Year
- CNTA N/A
- WGS $43.70
- Revenue Next Year
- CNTA N/A
- WGS $16.78
- P/E Ratio
- CNTA N/A
- WGS N/A
- Revenue Growth
- CNTA N/A
- WGS 29.41
- 52 Week Low
- CNTA $6.65
- WGS $2.47
- 52 Week High
- CNTA $18.97
- WGS $89.11
- Technical
- Relative Strength Index (RSI)
- CNTA 50.89
- WGS 52.66
- Support Level
- CNTA $16.02
- WGS $70.69
- Resistance Level
- CNTA $18.12
- WGS $83.78
- Average True Range (ATR)
- CNTA 1.08
- WGS 6.50
- MACD
- CNTA -0.08
- WGS -0.43
- Stochastic Oscillator
- CNTA 41.42
- WGS 42.10
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.
About WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.